The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Eric Joseph - JPMorgan - Analyst
: Thanks Mike. I think I might pick up first on the subcutaneous, the sub Q update here. You know, something that will support you have a profile
here that will support at least once every other month dosing. Is that, is that more or less defining the regimen that you anticipate moving into a
pivotal study or sort of what additional work or I guess if that's the floor, where's the ceiling in terms of how long you go in and in terms of dosing
interval?
Question: Eric Joseph - JPMorgan - Analyst
: Is that I guess in the views of the patients. I mean, it certainly makes sense. Fine. I need to inject myself, less times a year, Kim to. But I mean, market
feedback that you've kind of gar garnered to kind of speak to the how much dosing frequency is a pain point for physicians self administering.
Question: Eric Joseph - JPMorgan - Analyst
: So, your views on the non bl depleting CD 40 LY ascos 0.4 AR R based in general, how does that situate with your strategic thinking in the end
market?
Question: Eric Joseph - JPMorgan - Analyst
: Can I answer the same question for your view on T Cell engager, IG and Life sciences back whatever?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 14, 2025 / 12:30AM, TGTX.OQ - TG Therapeutics Inc at JPMorgan Healthcare Conference
Question: Eric Joseph - JPMorgan - Analyst
: Me, on your goal of being a leader in dynamic market share in 2025. Where are you positioned exiting in 2024 in terms of, share of new starts. And
then, how much do you think sort of DTC, direct to patient, excuse me, spend will kind of facilitate that metric.
Question: Eric Joseph - JPMorgan - Analyst
: And just thinking about sort of the partitioning of the CD 20 market between infused infusion center administered and and self administered or
sub Q. I guess is there any interaction between those markets that you're observing? I guess what does that mean to say is, the stickiness of the,
of the self administered market at DC. What do you, what are you observing in terms of retention there? And that likely being an opportunity for
at all for brib penetration?
Question: Eric Joseph - JPMorgan - Analyst
: Maybe just a final question Azer cell as that trial gets underway. Just what are maybe just oriented around sort of the initial kind of goals. In addition
to, assessing safety that would sort of support proof of concept really. And PP MS with this agent and yeah, and just sort of anticipated perhaps
read out timelines.
Question: Eric Joseph - JPMorgan - Analyst
: All right, great.
I think we'll leave it there for time.
| 
